Pneumococcal vaccination in adults

Current Infectious Disease Reports

Volumn 7, Issue 3, 2005, Pages 211-217

  Sherpa, Tsering Y ^b   Leaf, Howard L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CEPHALOSPORIN; DIPHTHERIA TOXIN; ERYTHROMYCIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HISTIDINE DERIVATIVE; LEVOFLOXACIN; MENINGOCOCCUS VACCINE; PENICILLIN G; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE VACCINE;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; DRUG CONJUGATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDEMA; ERYTHEMA; FEVER; GUILLAIN BARRE SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGENICITY; INCIDENCE; INJECTION PAIN; LICENCE; MORTALITY; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; PEDIATRICS; POPULATION RESEARCH; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

EID: 19144366023     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0037-6     Document Type: Review

References (60)

1. Austrian R, Douglas R, Schiffman G, et al.: Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976, 89:184.
2. Sisk JE, Whang W, Butler JC, et al.: Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003, 138:960-968.
3. Shapiro ED, Berg AT, Austrian R, et al.: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325:1453-1460.
4. Concepcion N, Frasch C: Pneumococcal type 22F polysaccharide adsorption improves the specificity of a pneumococcal polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272.
5. Törling J, Hedlund J, Konradsen HB, Örtqvist A: Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22:96-103.
6. Butler JC, Breiman RF, Campbell JF, et al.: Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993, 270:1826-1831.
7. Farr BM, Johnston BL, Cobb DK, et al.: Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995, 155:2336-2340.
8. Fine MJ, Smith MA, Carson CA, et al.: Efficacy of pneumococcal vaccination in adults. Arch Intern Med 1994, 154:2666-2677.
9. Nichol KL, Baken L, Wuorenma J, Nelson A: The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999, 159:2437-2442.
10. Simberkoff MS, Cross AP, Al-Ibrahim M, et al.: Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 315:1318-1327.
11. Ortqvist A, Hedlund J, Burman LA, et al.: Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998, 351:399-403.
12. Honkanen PO, Keistinen T, Miettinen L, et al.: Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999, 17:2493-2500.
13. Davis AL, Aranda CF, Schiffman G, Christianson LC: Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: a pilot study. Chest 1987, 92:204-212.
14. Jackson LA, Neuzil KM, Yu O, et al.: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
15. Watson L, Wilson BJ, Waugh N: Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002, 20:2166-2173.
16. Dear K, Holden J, Andrews R, Tatham D: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003, CD000422.
17. French N, Nakiyingi J, Carpenter LM, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355:2106-2111.
18. Breiman RF, Keller DW, Phelan MA, et al.: Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
19. Klein JO, Teele DW, Sloyer JL, et al.: Use of pneumococcal vaccine for prevention of recurrent episodes of otitis media. In Seminars in Infectious Disease. Edited by Weinstein L, Fields BN. New York: Thieme-Stratton Inc.; 1982:305-310.
20. Peter G, Klein JO: Pneumococcal vaccine. Pediatr Rev 1996, 17:335-341.
21. Douglas RM, Paton JC, Duncan SJ, et al.: Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983, 148:131-137.
22. Leinonen M, Sakkinen A, Kalliokoski R, et al.: Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in preschool age children. Pediatr Infect Dis 1986, 5:39-44.
23. Baltimore RS: New challenges in the development of a conjugate pneumococcal vaccine. JAMA 1992, 268:3366-3367.
24. Paton JC, Lock RA, Lee CJ, et al.: Purification and immunogenicity of genetically toxoided derivatives of pneumolysin and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 1991, 59:2297-2304.
25. Lee CJ, Lock RA, Andrew PW, et al.: Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide-pneumolysin conjugate. Vaccine 1994, 12:875-878.
26. Lu CH, Lee CJ, Kind P: Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate. Infect Immun 1994, 62:2754-2760.
27. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices: Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003, 52:739-740.
28. Klein DL, Ellis RW. Conjugate vaccines against Streptococcus pneumoniae. In New Generation Vaccines, edn 2. Edited by Levine MM, Woodrow GC, Kaper JB, Cobon GS. New York: Marcel Dekker Inc.; 1997:503-525.
29. Rennels MB, Edwards KM, Keyserling HL, et al.: Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998, 101:604-611.
30. Division of Microbiology and Infectious Diseases: Streptococcus pneumoniae. In The Jordan Report. Accelerated Development of Vaccines 1995. Edited by La Montagne M. Bethesda, MD: National Institute of Allergy and Infectious Diseases, National Institutes of Health; 1995:18-21.
31. Anderson EL, Kennedy DJ, Geldmacher KM, et al.: Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996, 128:649-653.
32. Butler JC, Breiman RF, Lipman HB, et al.: Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995, 171:885-889.
33. Kayhty H, Ahman H, Ronnberg PR, et al.: Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995, 172:1273-1278.
34. Leach A, Ceesay SJ, Bnya WN, Greenwood BM: Pilot trial of a pentavalent pneumococcal polysaccharide-protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996, 15:333-339.
35. Lock RA, Hansman D, Paton JC: Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 1992, 12:137-143.
36. Rennels MB, Edwards KM, Keyserling HL, et al.: Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998, 101:604-611.
37. Sorenson RU, Leiva LE, Giangrosso PA, et al.: Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998, 17:685-691.
38. Daum RS: Pneumococcal vaccines for children: an update. Pediatr Infect Dis J 1998, 17:823-824.
39. Obaro SK, Huo ZM, Banya WAS, et al.: A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997, 16:1135-1140.
40. Black S, Shinefield H, Baxter R, et al.: Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004, 23:485-489.
41. Dagan R, Melamed M, Muallam L: Reduction in the nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate vaccine. J Infect Dis 1996, 174:1271-1278.
42. Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
43. Flannery B, Heffernan R, Hadler J: Effect of widespread childhood vaccination on rates of pneumococcal disease among adults living with HIV/AIDS--United States, 1997-2003. Program and Abstracts of the 2004 Annual Meeting of the Infectious Diseases Society of America. Boston, MA, September 30-October 3, 2004.
44. Hoshino K, Watanabe H, Sugita R, et al.: Rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children. J Clin Microbiol 2002, 40:5357-5359.
45. Regev-Yochay G, Raz M, Dagan R, et al.: Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004, 38:632-639.
46. Fry AM, Zell ER, Schuchat A, et al.: Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002, 21:303-311.
47. Abraham Van Parijs B: Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004, 11:1362-1371.
48. Shelly MA, Pichichero Me, Treanor JJ: Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand J Infect Dis 2001, 33:542-544.
49. Mbelle N, Wasa A, Huebner R, et al.: Immunogenicity and impact on carriage of 9-valent pneumococcal vaccine given to infants in Soweto, South Africa. Proceedings from the Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 28-October 1, 1997.
50. Kaplan SL, Mason EO, Wald ER: Decrease in invasive pneumococcal infections in children among 8 children's hospitals in the United States after introduction of the 7-valent conjugate vaccine. Pediatrics 2004, 113:443-449.
51. Talbot T, Poehling K, Hartert T, et al.: Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004, 39:641-648.
52. Pletz M, Mcgee L, Klugman K: Levofloxacin resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and impact of the conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004, 48:3491-3497.
53. Whitney CG, Farley MM, Hadler J, et al.: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
54. Singleton JA, Greby SM, Wooten KG, et al.: influenza, pneumococcal, and tetanus toxoid vaccination of adults--United States, 1993-7. MMWR CDC Surveill Summ 2000, 49:39-62.
55. Influenza and pneumococcal vaccine coverage among persons aged > 65 years and persons aged 18-64 years with diabetes and asthma--United States, 2003. MMWR Recomm Rep 2004, 53:101007-101240.
56. Mieczkowski TA, Wilson SA: Adult pneumococcal vaccination: a review of physician and patient barriers. Vaccine 2002, 20:1383-1392.
57. Poolman JT: Pneumococcal vaccine development. Expert Rev Vaccines 2004, 3:597-604.
58. Briles DE, Hollingshead SK, Paton JC, et al.: Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 2003, 188:339-348.
59. Hamel J, Charland N, Pineau I, et al.: Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 2004, 72:2659-2670.
60. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-24.